SaaS Platforms Gain Traction in Clinical Trials Despite Spreadsheet Reliance
87% of clinical trial sites use decentralized elements, yet most still rely on spreadsheets. SaaS platforms are closing that...
NIH Grant Terminations Expose Structural Crisis at Clinical Research Sites
383 NIH-funded clinical trials terminated, exposing structural pressures on research sites managing funding cuts and protocol complexity simultaneously.
argenx to Acquire Forte Biosciences for $2.2 Billion, Gains FB102 Antibody
argenx acquires Forte Biosciences for $2.2 billion to gain FB102 antibody, an anti-CD122 treatment showing Phase 1b efficacy in...
WCG CenterWatch 2025 Report Shows AI Adoption Remains Uneven Across Clinical Research
WCG CenterWatch 2025 Report reveals where AI adoption stands in clinical research, showing implementation gaps between aspiration and execution.
WCG Report: 92% of Clinical Trial Organizations Plan AI Investment Within Two Years
92% of clinical trial organizations plan AI investment within two years, though only one-third currently use it meaningfully across...
CHMP Recommends Marketing Authorization for Obicetrapib in EU
CHMP recommends marketing authorization for obicetrapib in the EU, with Phase 3 trials showing up to 50% LDL-C reductions...
FDA Approves LYTENAVA, First Ophthalmic Bevacizumab for Wet AMD
FDA approves LYTENAVA, the first ophthalmic bevacizumab formulation for wet AMD, ending two decades of off-label use in retina...
Laminar Pharma Completes LAM561 Phase 2b/3 Trial in Glioblastoma
Laminar Pharma's LAM561 Phase 2b/3 trial in glioblastoma completes enrollment with topline overall survival data expected in Q2 2027.
Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint
Genmab and AbbVie clarify that epcoritamab Phase 3 trial missed primary endpoint for overall survival in transplant-ineligible DLBCL patients.
Atsena Gets EMA Orphan Status for ATSN-101 and ATSN-201
Atsena receives EMA orphan status for ATSN-101 and ATSN-201, with Phase 3 trials already underway for rare retinal diseases.